TenNor Therapeutics is a clinical-stage company with a sharp focus on research and development of new drugs to address unmet medical needs in infectious disease area.
TenNor possesses a unique, multi-targeting drug discovery platform and a differentiated, globally protected product development portfolio. These products have potential to address some of the major unmet medical needs in the treatment of gastrointestinal tract infections, medical device associated biofilm infections, bacterial vaginosis, multidrug-resistant tuberculosis and multidrug-resistant Gram-negative bacterial infections.
TenNor is led by an experienced management team with successful track record in research and development of new antimicrobial agents. The Board of Directors is formed by a group of experienced life science investors, many of them had experiences in building billion-dollar companies. The Scientific Advisory Board is consisted of several world-leading scientists and clinicians, including three Members of the National Academy of Sciences, USA.
TenNor adopts a highly efficient operating model, combining internal disease specific expertise with external CRO drug development capabilities to rapidly advance new drug development portfolio.